Reading FDMT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track FDMT free→Reading FDMT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track FDMT free→QuarterlyIQ Insights · FDMT
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 7, 2026, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the three months ended March 31, 2026. A copy of 4DMT’s press release, titled “4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones” is furnished pursuant to
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 25, 2026, the Board of Directors of 4D Molecular Therapeutics, Inc. (the “Company”) appointed Kristian Humer as the Company’s Principal Accounting Officer, effective immediately. In this role, Mr. Humer succeeds Ashoo Gupta, who continues to serve as the Company’s Vice President, Finance and Controller. Mr. Humer, age 51, has served as the…
Results of Operations and Financial Condition. On March 18, 2026, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the year ended December 31, 2025. A copy of 4DMT’s press release, titled “4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones” is furnished pursuant to
Unregistered Sales of Equity Securities. Issuance of Pre-Funded Warrants in Exchange for Common Stock On January 22, 2026, 4D Molecular Therapeutics, Inc. (the “Company”) entered into exchange agreements with RA Capital Healthcare Fund, L.P. (“RA Capital”) and Biotechnology Value Fund, L.P. and its affiliates (“BVF”), pursuant to which RA Capital exchanged 4,850,000 shares of the Company’s common stock for a pre-funded warrant to acquire 4,850,000 shares of the Company’s common stock, and BVF…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) Departure of President and Chief Operating Officer On December 31, 2025, in connection with his transition to a new part-time employment position, Fariborz Kamal, Ph.D., resigned as President and Chief Operating Officer of the Company effective immediately to pursue other opportunities. Dr. Kamal has agreed to transition to a part-time employme…
Results of Operations and Financial Condition. As of December 31, 2025, 4D Molecular Therapeutics, Inc. (the “Company”) estimates that it had approximately $514 million in cash, cash equivalents and marketable securities. This estimate of its cash, cash equivalents and marketable securities balance is preliminary and subject to completion of its financial closing procedures, including the completion of management’s reviews. Accordingly, the unaudited preliminary cash, cash equivalents and mar…
Other Events. On December 10, 2025, 4D Molecular Therapeutics, Inc. (the “Company”) announced its intention to implement protocol amendments (the “Amendments”) to the 4FRONT-1 and 4FRONT-2 Phase 3 clinical trials of 4D-150 in wet AMD (the “4FRONT Trials”) to increase target enrollment from 400 to 480 patients per trial. As previously disclosed, the 4FRONT Trials were initiated to provide >90% power for a primary endpoint of BCVA noninferiority of 4D-150 versus aflibercept 2mg Q8 weeks with a…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 17, 2025, Kristian Humer joined 4D Molecular Therapeutics, Inc. (the “Company”) as Chief Financial Officer and Principal Financial Officer. Mr. Humer, age 50, served as the Chief Financial Officer at Foghorn Therapeutics, Inc., a biotechnology company, from April 2024 to November 2025. From July 2021 to September 2023, Mr. Humer served…
Results of Operations and Financial Condition. On November 10, 2025, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the three months ended September 30, 2025. A copy of 4DMT’s press release, titled “4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones” is furnished pursuant to
Other Events. On November 6, 2025, 4D Molecular Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell (the “Offering”) 8,385,809 shares of its common stock (the “Shares”), par value $0.0001 per share (“Common Stock”), at an offering price of $10.51 per sh…
Results of Operations and Financial Condition. As of September 30, 2025, 4D Molecular Therapeutics, Inc. (the “Company”) estimates that it had approximately $372.2 million in cash, cash equivalents and marketable securities. This estimate of its cash, cash equivalents and marketable securities balance is preliminary and subject to completion of its financial closing procedures, including the completion of management’s reviews. Accordingly, the unaudited preliminary cash, cash equivalents and…
Entry into a Material Definitive Agreement. On October 31, 2025, 4D Molecular Therapeutics, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “Agreement”) with Otsuka Pharmaceutical Co., Ltd. (“Otsuka”). Pursuant to the Agreement, the Company granted Otsuka exclusive rights to develop and commercialize 4D-150 for ophthalmological diseases, including wet AMD and DME, in Japan, China, Australia, and other Asia-Pacific (“APAC”) markets. Otsuka has agreed to lead all re…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 30, 2025, the Board of Directors (the “Board”) of 4D Molecular Therapeutics, Inc. (the “Company”) appointed Ashoo Gupta as Principal Financial Officer and Principal Accounting Officer of the Company, effective immediately. Mr. Gupta, age 49, has served as the Company’s Vice President, Finance & Controller since June 2024. Prior to join…
Results of Operations and Financial Condition. On August 11, 2025, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the three months ended June 30, 2025. A copy of 4DMT’s press release, titled “4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones” is furnished pursuant to
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 27, 2025, Uneek Mehra informed 4D Molecular Therapeutics, Inc. (the “Company”) of his intent to resign as Chief Financial and Business Officer of the Company effective as of July 15, 2025 in order to pursue other opportunities. To facilitate the transition of his responsibilities, Mr. Mehra has agreed to provide advisory services and remain…
Other Events. 4FRONT Updates On July 2, 2025, the Company announced an update on timing regarding the Company’s Phase 3 program in wet age-related macular degeneration (“wet AMD”). The Company reported that initial enrollment and site activation for 4FRONT-1, the North American Phase 3 clinical trial of 4D-150 in wet AMD, have exceeded initial projections, reflecting continued strong engagement and enthusiasm from investigators and patients. The Company now expects 52-week topline data in the…
Results of Operations and Financial Condition. On May 8, 2025, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the three months ended March 31, 2025. A copy of 4DMT’s press release, titled “4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones” is furnished pursuant to
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.